# Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

> **NCT05913427** · PHASE2 · RECRUITING · sponsor: **Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia** · enrollment: 80 (estimated)

## Conditions studied

- Adrenocortical Carcinoma

## Interventions

- **DRUG:** Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
- **DRUG:** Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo

## Key facts

- **NCT ID:** NCT05913427
- **Lead sponsor:** Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-08
- **Primary completion:** 2027-06-08
- **Final completion:** 2027-06-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05913427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05913427, "Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05913427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*